We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02473731
Previous Study | Return to List | Next Study

A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02473731
Recruitment Status : Completed
First Posted : June 17, 2015
Last Update Posted : August 1, 2019
Information provided by (Responsible Party):
Celldex Therapeutics

Brief Summary:
The purpose of this study is to evaluate the activity and safety of KTN3379 in head and neck cancer patients and to explore downstream molecular pathways to identify tumor response and resistance mechanisms by evaluating various biomarkers before and after treatment.

Condition or disease Intervention/treatment Phase
Squamous Cell Carcinoma of the Head and Neck Biological: KTN3379 Phase 1

Detailed Description:
This is an open-label study in patients with squamous cell carcinoma of the head and neck (SCCHN) scheduled for surgery. Two cohorts of SCCHN patients, HPV negative and HPV positive, will be treated with KTN3379 to evaluate effects on ErbB3 phosphorylation and other biomarkers in tumor tissue. The KTN3379 treatment duration is within the expected window of time that elapses from initial patient evaluation by a surgeon to performance of surgery. Paired preoperative and postoperative tumor specimen analyses allow evaluation of proliferation, ErbB3 related biomarkers, pErbB3 modulation and pharmacodynamic changes in downstream molecular pathways.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients
Actual Study Start Date : October 2015
Actual Primary Completion Date : September 22, 2016
Actual Study Completion Date : October 10, 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: A
Treatment with KTN3379 in HPV positive head and neck cancer patients
Biological: KTN3379
Experimental: B
Treatment with KTN3379 in HPV negative head and neck cancer patients
Biological: KTN3379

Primary Outcome Measures :
  1. Change in pErbB3 levels in tumor tissue [ Time Frame: 4 weeks ]
    Reduction in pErbB3 levels

Secondary Outcome Measures :
  1. Number of patients with adverse events as a measure of safety and tolerability [ Time Frame: 6 weeks ]
    Adverse events (AEs), serious adverse events (SAEs), laboratory evaluations, radiological assessments, vital signs, electrocardiograms (ECGs), and physical examinations.

  2. Ki67 proliferative index in tumor tissue [ Time Frame: 4 weeks ]
    Ki67 proliferative index in tumor tissue before and after treatment

  3. Changes in tumor measurements (RECIST 1.1 measurements) [ Time Frame: 4 weeks ]
    RECIST 1.1 measurements before and after treatment

  4. Pharmacokinetics (Peak plasma concentrations of KTN3379 Trough plasma concentrations of KTN3379) [ Time Frame: 4 weeks ]
    Peak plasma concentrations of KTN3379 Trough plasma concentrations of KTN3379

  5. Anti drug antibodies [ Time Frame: 6 weeks ]
    Measurement of anti KTN3379 antibodies in blood

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histologically or cytologically confirmed primary, untreated SCCHN including variants. Patients must be candidates for surgical resection. Primary tumors of oral cavity, oropharynx, hypopharnyx or larynx are included.
  2. Written informed consent and any locally required authorization (e.g., HIPAA in the USA) obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations.
  3. Females of childbearing potential who are sexually active with a nonsterilized male partner must use 2 methods of effective contraception from screening, and must agree to continue using such precautions for 60 days after the final dose of KTN3379. Females of childbearing potential are defined as those who are not surgically sterile (i.e., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or those who are postmenopausal (defined as 12 months with no menses without an alternative medical cause)
  4. Nonsterilized males who are sexually active with a female partner of child-bearing potential must, with their partner, use 2 acceptable methods of effective contraception from Day 1 through 60 days after receipt of the final dose of KTN3379.
  5. Eastern Cooperative Oncology Group (ECOG) status of 0 or 1
  6. Adequate bone and marrow function as defined below:

    • Hemoglobin ≥ 10 g/dL
    • Absolute neutrophil count ≥ 1500/mm3
    • Platelet count ≥ 100,000/mm3
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 ×ULN
    • Bilirubin ≤ 1.5 × ULN except for cases of documented or suspected Gilbert's disease, in which bilirubin must be ≤ 5 × ULN
    • Serum creatinine ≤ 1.5 g/dL
    • Normal PT or INR and aPTT

Exclusion Criteria:

  1. Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment.
  2. Immunosuppressive or systemic steroids medication within 7 days before the first dose of KTN3379 (inhaled and topical corticosteroids are permitted).
  3. Another invasive malignancy within 2 years prior to enrollment except for localized prostate cancer, cervical carcinoma in situ, non-melanomatous carcinoma of the skin, or ductal carcinoma in situ of the breast that has/have been surgically cured
  4. Major surgical procedure within 30 days prior to Day 1 or incomplete recovery from any prior surgery
  5. Pregnancy or lactation
  6. Uncontrolled intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, uncontrolled or idiopathic hypotension, unstable angina pectoris, cardiac arrhythmia including atrial fibrillation, significant cardiac conduction abnormalities including prolongation of QTc interval or BBB, active peptic ulcer disease or gastritis, or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent
  7. Patients with a left ventricular cardiac ejection fraction < 50% as assessed by an echocardiogram or MUGA scan
  8. Patients with prior primary treatment for head and neck cancer (e.g. chemoradiation or radiation alone).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02473731

Layout table for location information
United States, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States, 94115
United States, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
Celldex Therapeutics
Layout table for additonal information
Responsible Party: Celldex Therapeutics
ClinicalTrials.gov Identifier: NCT02473731    
Other Study ID Numbers: KTN3379-CL-002
First Posted: June 17, 2015    Key Record Dates
Last Update Posted: August 1, 2019
Last Verified: May 2017

Layout table for additional information
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Celldex Therapeutics:
Additional relevant MeSH terms:
Layout table for MeSH terms
Head and Neck Neoplasms
Squamous Cell Carcinoma of Head and Neck
Carcinoma, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms by Site